Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam

Overview

Journal Cancer Control

Specialty Oncology

Date 2019 Jul 11

PMID 31290350

Citations 9

Authors

Van Quang Le

Van Hieu Nguyen

Van Hung Nguyen

Thanh Long Nguyen

Staci L Sudenga

Le Huy Trinh

Van Tung Nguyen

Thi Thu Huong Nguyen

Affiliations

Soon will be listed here.

Abstract

Epidemiological characteristics of hepatocellular carcinoma (HCC) in Southern Vietnam has been well reported as in Globocan 2018 while data from the North has still not been fully presented. Therefore, we conducted this retrospective descriptive study on 198 advanced HCC patients treated at 3 major hospitals in Northern Vietnam to describe demographic features, HCC risk factors, and correlation among them in patients with advanced HCC. This information will lead to prevention efforts and provide information for allocating funds for treatment. The median age at diagnosis was 57 years (range: 19-86) and the male/female ratio was 8.9/1. The proportions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection were 81.3% and 5.6%, respectively. Hepatitis C virus infection rate was significantly higher in patients <50 years old (12.5% vs 3.3%, = .016). There was no significant difference in age or viral hepatitis infection status by gender. Only 7.6% of patients diagnosed with advanced HCC were asymptomatic. In conclusion, with the high rate of HBV infection among patients with advanced HCC, it is necessary for increasing prevention efforts in HBV screening. Furthermore, HCV infection should be noticed in patients with advanced HCC younger than 50 years old.

Citing Articles

Expression of SUMO and NF-κB genes in hepatitis B virus-associated hepatocellular carcinoma patients: An observational study.

Khai N, Huy D, Thi Trang D, Minh N, Tien T, Phuong N Medicine (Baltimore). 2024; 103(26):e38737.

PMID: 38941371 PMC: 11466154. DOI: 10.1097/MD.0000000000038737.

Surveillance and treatment of primary hepatocellular carcinoma (aka. STOP HCC): protocol for a prospective cohort study of high-risk patients for HCC using GALAD-score.

Truong T, Pham T, Hoang L, Nguyen V, Dao H, Dao D BMC Cancer. 2023; 23(1):875.

PMID: 37723439 PMC: 10506187. DOI: 10.1186/s12885-023-11167-9.

Survival Outcome and Prognostic Factors Among Patients With Hepatocellular Carcinoma: A Hospital-Based Study.

Le D, Nguyen T, Nguyen D, Nguyen D, Nguyen L Clin Med Insights Oncol. 2023; 17:11795549231178171.

PMID: 37359273 PMC: 10286205. DOI: 10.1177/11795549231178171.

Detection of sFas, sCD137, and IL-27 Cytokines as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis.

Do X, Le M, Nguyen T, Le T, Nguyen X, Mai T J Hepatocell Carcinoma. 2023; 10:783-793.

PMID: 37260529 PMC: 10228584. DOI: 10.2147/JHC.S409649.

Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts.

Brown R, Goulder P, Matthews P Wellcome Open Res. 2022; 7:32.

PMID: 36212217 PMC: 9520633. DOI: 10.12688/wellcomeopenres.17601.2.

References

Llovet J, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3):329-38. DOI: 10.1055/s-2007-1007122. View

Kuper H, Tzonou A, KAKLAMANI E, Hsieh C, Lagiou P, Adami H . Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000; 85(4):498-502. View

Kuper H, Tzonou A, KAKLAMANI E, Hadziyannis S, Tasopoulos N, Lagiou P . Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays. Cancer Causes Control. 2000; 11(2):171-5. DOI: 10.1023/a:1008951901148. View

Evans A, Chen G, Ross E, Shen F, Lin W, London W . Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev. 2002; 11(4):369-76. View

Le G, Gomez S, Clarke C, Glaser S, West D . Cancer incidence patterns among Vietnamese in the United States and Ha Noi, Vietnam. Int J Cancer. 2002; 102(4):412-7. DOI: 10.1002/ijc.10725. View

Ngaon L, Yoshimura T . Liver Cancer in Viet Nam: Risk Estimates of Viral Infections and Dioxin Exposure in the South and North Populations. Asian Pac J Cancer Prev. 2003; 2(3):199-202. View

Tran H, Ushijima H, Quang V, Phuong N, Li T, Hayashi S . Prevalence of hepatitis virus types B through E and genotypic distribution of HBV and HCV in Ho Chi Minh City, Vietnam. Hepatol Res. 2003; 26(4):275-280. DOI: 10.1016/s1386-6346(03)00166-9. View

Bonilla Guerrero R, Roberts L . The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol. 2005; 42(5):760-77. DOI: 10.1016/j.jhep.2005.02.005. View

Michielsen P, Francque S, van Dongen J . Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005; 3:27. PMC: 1166580. DOI: 10.1186/1477-7819-3-27. View

10.

Yu M, Tong M, Govindarajan S, Henderson B . Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst. 1991; 83(24):1820-6. DOI: 10.1093/jnci/83.24.1820. View

11.

Toan N, Song L, Kremsner P, Duy D, Binh V, Koeberlein B . Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology. 2006; 43(6):1375-84. DOI: 10.1002/hep.21188. View

12.

Perz J, Armstrong G, Farrington L, Hutin Y, Bell B . The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4):529-38. DOI: 10.1016/j.jhep.2006.05.013. View

13.

Yang H, Yeh S, Chen P, Iloeje U, Jen C, Su J . Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(16):1134-43. PMC: 2518166. DOI: 10.1093/jnci/djn243. View

14.

Lok A, Seeff L, Morgan T, Di Bisceglie A, Sterling R, Curto T . Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2008; 136(1):138-48. PMC: 3749922. DOI: 10.1053/j.gastro.2008.09.014. View

15.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

16.

Rimassa L, Santoro A . Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009; 9(6):739-45. DOI: 10.1586/era.09.41. View

17.

Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S . Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol. 2011; 46(10):1230-7. DOI: 10.1007/s00535-011-0431-9. View

18.

Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M . Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst. 2011; 103(22):1686-95. PMC: 3216968. DOI: 10.1093/jnci/djr395. View

19.

Mittal S, El-Serag H . Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013; 47 Suppl:S2-6. PMC: 3683119. DOI: 10.1097/MCG.0b013e3182872f29. View

20.

Huy Do S, Yamada H, Fujimoto M, Ohisa M, Matsuo J, Akita T . High prevalences of hepatitis B and C virus infections among adults living in Binh Thuan province, Vietnam. Hepatol Res. 2014; 45(3):259-68. DOI: 10.1111/hepr.12350. View